SDGR

Schrodinger, Inc. (SDGR) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Schrodinger, Inc. operates two primary segments: Software (licensing physics-based computational platforms for drug and materials discovery) and Drug Discovery (proprietary programs and collaborations with biopharmaceutical companies). The company is a large accelerated filer incorporated in Delaware.

Key Financial Metrics

Segment Performance (Q3 2025): Software revenue was $40.9M (Gross Margin: 73%). Drug Discovery revenue was $13.5M (Gross Margin: -12.7%).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 54% year-over-year (Q3) and 41% (9M), driven by a 295% surge in Drug Discovery revenue and 28% growth in Software revenue.
• Novartis Collaboration: A major driver of growth was the new research collaboration with Novartis Pharma AG, initiated in November 2024 with a $150M upfront payment. The company recognized $8.8M in revenue from this agreement in Q3 2025.
• Operating Expenses: Total operating expenses decreased 14% in Q3 and 8% in the 9M period, reflecting a restructuring announced in May 2025 that reduced headcount by approximately 60 employees (7% of workforce).
• Equity Investments: The company reported a $9.7M unrealized gain on its investment in Structure Therapeutics in Q3 2025. In contrast, Q3 2024 included a $19.1M gain on the Morphic investment prior to its acquisition by Eli Lilly.
• Cash Flow: Operating cash flow turned positive, providing $30.0M in the first nine months of 2025, compared to a use of $126.3M in the same period in 2024. This improvement was largely due to cash collections from the Novartis collaboration.

Guidance, Outlook, and Risks

• Restructuring Impact: The May 2025 restructuring is expected to reduce annualized operating expenses by approximately $30M and result in total savings of ~$70M when combined with the phasing out of independent clinical development activities.
• Clinical Pipeline Updates:
  • SGR-1505 (MALT1 inhibitor): Phase 1 data showed the drug was well-tolerated with preliminary clinical activity. Received Fast Track designation for Waldenström macroglobulinemia in June 2025.
  • SGR-3515 (Wee1/Myt1 inhibitor): Phase 1 dosing initiated in July 2024; initial data expected in H1 2026.
  • SGR-2921 (CDC7 inhibitor): Discontinued in August 2025 due to safety concerns (two deaths in AML patients).
• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($401M) are sufficient to fund operations for at least the next 24 months.
• Risks: Key risks include the uncertainty of clinical trial outcomes, reliance on third-party CROs, potential impact of U.S. tariffs on supply chains, and the need to achieve profitability through software sales or collaboration milestones. The company maintains a full valuation allowance on deferred tax assets.

Investor Verification Checklist

• Novartis Milestone Recognition: Verify the timing and probability of future milestone payments from the Novartis agreement ($2.27B potential) and the specific revenue recognition policies applied to the $150M upfront fee.
• SGR-1505 Clinical Data: Monitor upcoming data presentations (ASCO/ASH) for SGR-1505 to confirm safety and efficacy trends, which are critical for partnership valuation.
• Restructuring Savings Realization: Track whether the projected $30M annualized cost savings from the May 2025 workforce reduction materialize in subsequent quarters.
• Equity Investment Volatility: Assess the impact of fair value changes in Structure Therapeutics and other equity stakes on net income, as these are non-cash items that significantly affect reported losses.
• Customer Concentration: Note that one customer accounted for 47% of accounts receivable as of September 30, 2025, creating collection risk.